Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

8.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

18.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.8K
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

17.3K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
17.3K
RNA Interference01:23

RNA Interference

28.3K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.3K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The atypical E3 ligase HOIL-1 safeguards the ribosome during cellular stress.

Nature cell biology·2026
Same author

Correction: Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation.

RSC chemical biology·2026
Same author

Quantitative Degradation Rate Assessment of bioPROTACs Based on Peptide Degrons, E3 Domains, Adapters and Conjugated Small Molecules.

ACS chemical biology·2026
Same author

Design and Application of Cereblon-Recruiting Prodegraders.

Journal of the American Chemical Society·2025
Same author

Next steps for targeted protein degradation.

Cell chemical biology·2024
Same author

An atypical E3 ligase safeguards the ribosome during nutrient stress.

bioRxiv : the preprint server for biology·2024

Related Experiment Video

Updated: Feb 28, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.3K

Targeted protein knockdown using small molecule degraders.

Kanak Raina1, Craig M Crews2

  • 1Arvinas LLC, New Haven, CT 06511, United States.

Current Opinion in Chemical Biology
|June 13, 2017
PubMed
Summary
This summary is machine-generated.

New small molecules, like Proteolysis Targeting Chimeras (PROTACs), offer a novel approach to degrade previously

More Related Videos

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

13.2K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K

Related Experiment Videos

Last Updated: Feb 28, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.3K
A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

13.2K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K

Area of Science:

  • Pharmacology
  • Chemical Biology
  • Drug Discovery

Background:

  • Traditional drug design focuses on inhibiting protein active sites, excluding many 'undruggable' targets.
  • Protein-protein interaction (PPI) inhibitors and allosteric modulators represent advancements but still have limitations.
  • A significant number of disease-relevant proteins remain inaccessible to conventional small molecule therapeutics.

Purpose of the Study:

  • To review the preclinical development of small molecule-based protein degraders.
  • To highlight recent technological advancements in protein degradation.
  • To discuss the potential of Proteolysis Targeting Chimeras (PROTACs) as therapeutic agents.

Main Methods:

  • Exploration of small molecules that recruit cellular proteostasis machinery for targeted protein degradation.
  • Focus on Proteolysis Targeting Chimeras (PROTACs) as a key technology class.
  • Summary of preclinical data and technological improvements in the field.

Main Results:

  • Emergence of novel small molecules capable of targeting previously undruggable proteins.
  • PROTACs demonstrate a paradigm shift in chemical genetics by inducing targeted protein degradation.
  • Significant advancements position PROTAC technology for clinical translation.

Conclusions:

  • Small molecule-based protein degraders, particularly PROTACs, offer a promising new modality for drug discovery.
  • This approach broadens the scope of druggable targets beyond traditional enzyme and receptor inhibition.
  • PROTACs are poised to enter clinical trials, representing a significant advancement in therapeutic development.